Bevacizumab for advanced breast cancer

Tiffany A Traina; Hope S Rugo; Maura Dickler

doi:10.1016/j.hoc.2007.03.006

Bevacizumab for advanced breast cancer

Hematol Oncol Clin North Am. 2007 Apr;21(2):303-19. doi: 10.1016/j.hoc.2007.03.006.

Authors

Tiffany A Traina¹, Hope S Rugo, Maura Dickler

Affiliation

¹ Department of Medicine, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. [email protected]

PMID: 17512451
DOI: 10.1016/j.hoc.2007.03.006

Abstract

Tumor angiogenesis is essential for the growth and metastasis of solid tumors. In breast cancer, increased levels of vascular endothelial growth factor (VEGF) have been associated with poor prognosis in lymph node-positive and lymph node-negative patients. In addition to its prognostic significance, VEGF is now a validated target in the treatment of breast cancer. Bevacizumab, an anti-VEGF antibody, has demonstrated significant clinical benefit in several solid tumors. In this article the authors discuss the data pertaining to bevacizumab and other antiangiogenic agents for the treatment of patients who have advanced breast cancer.

Publication types

Review

MeSH terms

Angiogenesis Inhibitors / administration & dosage
Angiogenesis Inhibitors / adverse effects
Angiogenesis Inhibitors / therapeutic use*
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Bevacizumab
Breast Neoplasms / blood supply
Breast Neoplasms / drug therapy*
Breast Neoplasms / metabolism
Breast Neoplasms / pathology
Clinical Trials as Topic
Female
Humans
Neoplasm Metastasis
Neovascularization, Pathologic / drug therapy*
Neovascularization, Pathologic / metabolism
Vascular Endothelial Growth Factor A / biosynthesis

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
VEGFA protein, human
Vascular Endothelial Growth Factor A
Bevacizumab